Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 5/20 | 0.89 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.89 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.89 |
| ▸ | AURKB | Q96GD4 | 18/20 | 0.87 |
| ▸ | FLT3 | P36888 | 3/20 | 0.87 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.87 |
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13153153 | 0.94 | CHEK1 (1.00) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588184 | 0.94 | CHEK1 (0.78) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13617843 | 0.90 | AURKB (1.00) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588180 | 0.88 | CHEK1 (0.88) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155484 | 0.88 | CHEK1 (0.85) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155431 | 0.85 | AURKB (0.79) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13983735 | 0.84 | CHEK1 (0.82) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13155483 | 0.84 | CHEK1 (0.75) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL12588157 | 0.84 | AURKB (0.89) | CHEK1RPS6KA3IRAK4AURKBFLT3 | |
| SCHEMBL13983916 | 0.84 | AURKB (0.74) | CHEK1RPS6KA3IRAK4AURKBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010124009-A2 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | SCHERING CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | CHEK1 61/4885RPS6KA3 1157/4885IRAK4 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.